Biogen (NASDAQ:BIIB) Given New $228.00 Price Target at HC Wainwright

Biogen (NASDAQ:BIIB) had its price objective increased by HC Wainwright from $194.00 to $228.00 in a research note issued to investors on Monday morning, MarketBeat.com reports. They currently have a buy rating on the biotechnology company’s stock.

Several other research analysts have also commented on the stock. Wall Street Zen lowered shares of Biogen from a “buy” rating to a “hold” rating in a research note on Sunday, November 9th. UBS Group started coverage on Biogen in a report on Tuesday, January 6th. They issued a “neutral” rating and a $185.00 target price for the company. Piper Sandler restated a “neutral” rating and set a $157.00 target price (up previously from $118.00) on shares of Biogen in a report on Friday, November 21st. Stifel Nicolaus increased their price target on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research report on Friday. Finally, Robert W. Baird cut their price objective on shares of Biogen from $255.00 to $250.00 in a report on Friday, October 31st. Thirteen investment analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $206.21.

Biogen Stock Down 3.7%

BIIB stock opened at $193.81 on Monday. The stock has a market cap of $28.43 billion, a P/E ratio of 22.00, a PEG ratio of 1.70 and a beta of 0.16. Biogen has a twelve month low of $110.04 and a twelve month high of $202.41. The business’s 50-day moving average price is $177.26 and its 200-day moving average price is $157.48. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same quarter in the prior year, the company posted $3.44 earnings per share. The business’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities research analysts forecast that Biogen will post 15.83 EPS for the current year.

Insider Buying and Selling at Biogen

In related news, insider Priya Singhal sold 748 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total value of $134,116.40. Following the completion of the transaction, the insider directly owned 6,271 shares in the company, valued at approximately $1,124,390.30. This represents a 10.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.18% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Biogen

Several large investors have recently bought and sold shares of the business. Empowered Funds LLC boosted its stake in Biogen by 64.9% in the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after acquiring an additional 2,777 shares in the last quarter. Focus Partners Wealth lifted its stake in shares of Biogen by 172.2% in the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock worth $1,392,000 after acquiring an additional 6,436 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Biogen in the 2nd quarter worth $216,000. Blair William & Co. IL raised its holdings in Biogen by 11.8% during the second quarter. Blair William & Co. IL now owns 14,844 shares of the biotechnology company’s stock worth $1,864,000 after purchasing an additional 1,561 shares in the last quarter. Finally, Callan Family Office LLC purchased a new stake in Biogen in the 2nd quarter valued at approximately $308,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat guidance: Biogen reported fourth‑quarter and FY results ahead of expectations, prompting analysts to raise forecasts and price targets — a direct earnings-driven positive catalyst. Biogen Posts Q4 Beat, Analysts Raise Price Targets
• Positive Sentiment: Regulatory progress for Leqembi: A biologics license application for a subcutaneous formulation of Leqembi was designated for priority review — this could expand prescribing convenience and bolster long‑term franchise value. Biologics License Application for Subcutaneous LEQEMBI Designated for Priority Review
• Positive Sentiment: Geographic expansion: Reports that China fast‑tracked at‑home use of Leqembi add another potential growth market for the Alzheimer’s franchise. Biogen stock to pop again? China fast-tracks Leqembi
• Positive Sentiment: Big analyst upgrades: RBC raised its price target to $233 (Outperform) and HC Wainwright raised its target to $228 (Buy), both signalling double‑digit upside from current levels and reflecting confidence in Leqembi and cash‑flow prospects. RBC Raises Price Target on Biogen to $233
• Neutral Sentiment: Mixed/neutral analyst stances: Several shops (Citigroup, Piper Sandler, Wedbush, Truist) nudged price targets higher but kept Neutral/Hold ratings, leaving investor guidance mixed. Analyst Price Target Moves (Citigroup, Piper, Wedbush, Truist)
• Negative Sentiment: Franchise pressure and execution risk: Analysis points to MS‑franchise weakness and near‑term growth limits, which keep some analysts cautious despite the Alzheimer’s upside. Biogen FY25 Earnings: Stable EPS Amid MS Franchise Pressure

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.